Richard Conway RichardPAConway
1 year 10 months ago
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
David Liew drdavidliew
1 year 10 months ago
What agent to pick after a TNFi has failed: another TNFi or a non-TNFi?
Would a TNFi drug conc help (i.e. if low, increased clearance due to secondary failure)?
In this RCT @maartenskliniek, this TDM approach was no better than random selection. Argh
#ACR24 ABST0533 @RheumNow https://t.co/3h8o4ARZG3
David Liew drdavidliew
1 year 10 months ago
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow https://t.co/hErZVfs08k
Mrinalini Dey DrMiniDey
1 year 10 months ago
❓What factors influence patient participation in rheumatology #ClinicalTrials?
📌 Come to poster 0366 to find out!
👨🏻⚕️ @KKouranloo & @chriswincup report results from a UK study, showing marked differences by ethnicity & RMD
@RheumNow Ab0366 #ACR24 https://t.co/kAqGJmNiPt
David Liew drdavidliew
1 year 10 months ago
Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work:
JAKi, TNFi quicker than tocilizumab, abatacept
Even though they all get to a similar place eventually, some get there quicker
(but worth any safety tradeoffs?)
#ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi
Eric Dein ericdeinmd
1 year 10 months ago
Spatial Proteomics study for TEN
Marked enrichment of type I and II interferon and STAT1 activation
Pathways suggests benefit for JAKi in this condition
Clinical response in case photos, suggests benefit of pursuing clinical trial
Year in Review #ACR24 Bridges
@RheumNow https://t.co/K34lbnenRH
sheila RHEUMarampa
1 year 10 months ago
Have you ever tried giving Semaglutide in addressing weight loss among your patients with #osteoarthritis and #obesity?
@RheumNow #ACR
David Liew drdavidliew
1 year 10 months ago
Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings.
Whether all of this is appropriate or not, we'll have to see...
#ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5
Adela Castro AdelaCastro222
1 year 10 months ago
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9
Eric Dein ericdeinmd
1 year 10 months ago
Synovial fibroblast gene expression
Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons
May help explain pain in RA, possible targets
Year in Review #ACR24 Bridges
@RheumNow https://t.co/kpDVKh0C9O
Eric Dein ericdeinmd
1 year 10 months ago
Role of X chromosome in autoimmune disease?
SLE increased in Klinefelter (XXY), decreased in Turner’s (XO)
X chromosome inactivation with Xist
Inductively transgenic expression of Xist in male mice induces autoantibodies
Year in Review #ACR24 Bridges
@RheumNow https://t.co/M88f0v0kpe
Patricia Harkins DrTrishHarkins
1 year 10 months ago
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients!
Don’t forget the 5Ms!
🧠Mind (cog/mood)
💊Medication (PIM)
🏃♀️Mobility
👉Multi-complexity
💪🏻Matters most (pt priority)
@RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX
Gabriela Martinez Zayas, MD MartinezZayasMd
1 year 10 months ago
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Brian Jaros, MD Dr_Brian_MD
1 year 10 months ago
EGPA: To RTX or not to RTX?
French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy
Huge anticipation for these results, hopefully next year!
#ACR24 @RheumNow https://t.co/POelLpirrI
